Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Cassava Sciences Inc (FLNA) Price & Performance

Enphase Energy IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Cassava Sciences Inc — how do they compare? Enphase Energy Inc trades at $41.07 (market cap $5.81B), while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: Enphase Energy Inc is far larger — about 109.3× Cassava Sciences Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ENPHFLNA
Market Cap
$5.81B$53.14M
Sector
TechnologyHealth
52-Week High
$72.33$4.64
52-Week Low
$26.12$1.09
Enterprise Value
$5.46B-$33.43M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enphase Energy Inc

Enphase Energy (ENPH) trades at $41.59, down 7.55% in the past 24 hours, reflecting recent bearish pressure. The stock shows a mixed technical picture with support near $39 and resistance at $44, while fundamentals indicate solid profitability with a 44.23% gross margin and consistent earnings beats in recent quarters. Recent news highlights product expansions in Europe and Australia, alongside positive analyst coverage citing long-term tailwinds despite short-term challenges.

Outlook remains cautiously optimistic with a consensus price target of $42.79, slightly above current levels. Key opportunities include global product rollouts and high margins, but risks involve revenue volatility, competitive pressures, and ongoing legal scrutiny. Investors should weigh strong fundamentals against near-term stock weakness and market sentiment shifts.

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA